Latest recommendation updates
ATAGI have not published any updated advice or recommendations since 7 July 2022.
Recent ATAGI considerations
On Wednesday 13 July 2022, ATAGI met to consider the latest developments relating to COVID-19 immunisation. As of 11 July 2022, over 60 million doses of COVID-19 vaccines have been administered in Australia.
Impact of COVID-19 vaccination on children aged 6 months to 4 years
ATAGI have continued reviewing data on the impact of COVID-19 vaccination on children aged 6 months to 4 years, including the burden of disease in this age group in both Australian and international contexts.
Currently, there are no TGA-approved vaccines for use in this age group.
Reinfection and timing of COVID-19 vaccine doses
ATAGI notes there is now a difference between the interval that defines re-infection (4 weeks) and the recommended minimum interval between infection and subsequent vaccine doses (3 months) as per the 8 July 2022 statement from the Australian Health Protection Principal Committee (AHPPC).
Evidence suggests that BA.4/5 is associated with a higher re-infection rate compared to previous variants, and this is likely to be due to immune evasion.
